Application of Supply Chain Techniques Tailored for the U.S. Pharmaceutical Industry Considering Regulatory Constraints

The U.S. pharmaceutical industry is situated within one of the most regulated environments globally, while also serving as the world's innovation engine with annual revenues greater than $550 billion. In an effort to balance efficiency, safety, and regulatory compliance, and to vary regulatory constraints by individual organizations and products, industry leaders employ numerous supply-chain concepts that can be characterized by the following areas of focus: lean (manufacturing), cold-chain (biologics and mRNA vaccines), digitalization (traceability), inventory optimization (waste mitigation), supplier collaboration (DEA quota management), and risk management (FMEA scenario development) methods. Each of these categories utilizes specific concepts and practices, while also customizing solutions to adhere to U.S. laws and regulations established by the FDA, DEA, CDC, and HHS. Lean concepts emphasize the elimination of non-value-added steps while actualizing cGMP validations within defined standard operating procedures. Cold-chain solutions for biopharmaceutical manufacturers of biologics and mRNA vaccines utilize a variety of methods to maintain specific temperature requirements of 2–8 °C or -70 °C by utilizing validated insulated shippers, GPS-enabled IoT sensors, and U.S. Pharmacopeia guidelines. Digitalization solutions respect the stewardship of federal regulations like 21 CFR Part 11 and Health Insurance Portability and Accountability Act (HIPAA) privacy rules in order to provide traceability of drug distribution by employing serialization under the Drug Supply Chain Security Act (DSCSA). Inventory optimization focuses on employing machine-learning capabilities to forecast demand while balancing waste versus expiration date leads to improved buy context. The resulting buy context has led to prior waste reduction by 12% and greater than 99.5% on-shelf availability. Supplier collaboration utilizes the DEA quota management system concept to synchronize API schedules and controlled-drug shipments for pharmaceutical firms. Risk management frameworks integrate FMEA plans for scenario development with prepared metrics for when presentations are regulated by the FDA. Lastly, examples of case studies that utilized these integration practices discuss examples utilized by Pfizer, Johnson & Johnson, Moderna, and Merck of the regulatory framework to define and implement practices that will produce improvement, resilience, and patient safety outcomes. Strategic recommendations allow U.S. pharmaceutical firms to maintain and sustain regulatory obligations, improve and optimize operations, and ensure the continuity of supply and demand despite target-heavy issues. This approach will assist U.S. pharmaceutical firms at meeting regulatory expectations and remaining innovative amid a host of challenges.